Xin Lang Cai Jing·2026-01-22 18:09Group 1 - The core point of the article is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has approved the spin-off of its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange [1] - The proposed initial issuance of H-shares will not exceed 25% of the total share capital after issuance, with an option for an additional 15% through an over-allotment [1] - The board believes that the spin-off aligns with regulatory requirements and will help the company focus on its core business, enhance independence, and unlock the valuation potential of its vaccine business segment [1] Group 2 - After the spin-off, Shanghai Fosun Pharmaceutical is expected to maintain control over Fosun Antigen [1] - Fosun Antigen serves as the vaccine business platform for Shanghai Fosun Pharmaceutical, engaging in the research, production, and sales of vaccines [1] - Currently, Fosun Antigen has launched products including human rabies vaccine and influenza virus split vaccine [1]